Chem-seq

Last updated

Chem-seq is a technique that is used to map genome-wide interactions between small molecules and their protein targets in the chromatin of eukaryotic cell nuclei. [1] The method employs chemical affinity capture coupled with massively parallel DNA sequencing to identify genomic sites where small molecules interact with their target proteins or DNA. It was first described by Lars Anders et al. in the January, 2014 issue of "Nature Biotechnology".

Contents

Uses of Chem-seq

A substantial number of small-molecule ligands, including therapeutic drugs, elicit their effects by binding specific proteins associated with the genome. Mapping the global interactions of these chemical entities with chromatin in a genome-wide manner could provide insights into the mechanisms by which a small molecule influences cellular functions. When combined with other chromatin analysis techniques such as ChIP-seq, [2] Chem-seq can be utilized to investigate the genome-wide effects of therapeutic modalities and to understand the effects of drugs on nuclear architecture in various biological contexts. In a broader sense, these methods will be useful to enhance our understanding of the therapeutic mechanisms through which small molecules modulate the function and activity of genome-associated proteins. [1] Through the identification of the cellular targets of a drug, it becomes possible to gain an increased understanding of the causes of side effects and toxicity in the early stages of drug development, which should help to reduce the attrition rate in development. [3]

Workflow of Chem-seq

Chem-seq Workflow Chem-seq Workflow.png
Chem-seq Workflow

Chem-seq relies on the ability to create a biotinylated version of a small molecule of interest to allow for downstream affinity capture. Chem-seq can be carried out either In vitro or In vivo , although the results from each have proven to be highly similar. [1]

In vivo Chem-seq

During In vivo Chem-seq, [1] cultured cells in medium are treated simultaneously with either a biotinylated version of the small molecule under study or DMSO (as a control) and 1% formaldehyde for the crosslinking of DNA, proteins and small molecules. DNA is then extracted from the cells, sonicated and enriched for regions containing the biotinylated molecule of interest by incubation with streptavidin magnetic beads, which have a very high affinity for biotin. The enriched DNA fraction is then purified, eluted from the beads and subjected to next generation sequencing. Genomic regions enriched in the Chem-seq library relative to the control are associated with the small molecule under study.

In vitro Chem-seq

In vitro Chem-seq [1] begins with the crosslinking of cultured cells in medium with 0.5% formaldehyde. Cell nuclei are then harvested from the cells and their DNA is extracted. This extract is sonicated before being incubated with streptavidin magnetic beads that are bound to a biotinylated form of our compound of interest. This provides an opportunity for the small molecule of interest to interact with its target genomic regions. These genomic regions are then isolated using a magnet and subjected to next generation sequencing and analysis to determine regions enriched for our small molecule of interest.

Sensitivity

Chem-seq was tested on three classes of drugs using MM1.S multiple myeloma cells to: [1]

1) Investigate the genome-wide binding of the bromodomain inhibitor JQ1 to the BET bromodomain family members BRD2, BRD3 and BRD4

2) Map the genomic binding sites of AT7519, an inhibitor of the cyclin dependent kinase CDK9, and

3) Study how the DNA intercalating agent psoralen interacts with genomic DNA in vivo.

In the first two trials, Chem-seq signals occurred at genomic sites occupied by the drugs' corresponding target proteins and were concordant with ChIP-seq results. However, bio-AT7519 produced weaker Chem-seq signals compared to those observed for bio-JQ1. There was also a substantial number of loci that were not co-occupied by bio-AT7519 and its target CDK9 which might be attributed to the weaker signal obtained for bio-AT7519 or because AT7519 can bind and inhibit other cyclin-dependent kinase like cdks 1, 2, 4, 5. [1] [3] In a third experiment, Chem-seq was efficient in mapping genomic binding sites of the DNA intercalating agent psoralen and showed that bio-psoralen preferentially binds to the transcription start site of active genes.

Advantages and Limitations

Advantages

Chem-seq is the first method that provides researchers with a way of determining the location of small molecules throughout the genome. It can be used in conjunction with ChIP-seq to cross reference the location of certain drugs with DNA binding proteins, like transcription factors, to discover novel interactions and aid in characterizing the molecular mechanisms through which small molecules affect the genome.

Because it uses next generation sequencing to determine small molecule binding sites, Chem-seq has a very high sensitivity and is compatible with other next generation sequencing based methods.

Previously, another similar technique known as chromatin affinity-precipitation (ChAP) assay was used to map the sites of interaction of metabolic compounds in the yeast genome, [4] but Chem-seq is the first method to assess the genome-wide localization of small molecules in mammalian cells.

Limitations

For Chem-seq to be feasible, the small molecule under study must be amenable to biotinylation without disruption of its natural binding properties. This is simply not possible with certain small molecules and even when it is, the process can require expertise in organic chemistry. Once synthesized, the binding properties of the biotinylated compound must be tested. To date, this has been accomplished by comparing the binding kinetics of the biotinylated and unmodified compounds, [1] a process that requires prior knowledge of the proteins that the compound binds.

The locations of Bio-JQ1 throughout the genome, as determined using Chem-seq, are almost identical to the ChIP-seq derived locations of the JQ1’s known target protein, BRD4. [1] Although this may be viewed as a testament to the accuracy of the method it also highlights redundancies between the two techniques, especially when target proteins are previously known.

Related Research Articles

DNA footprinting is a method of investigating the sequence specificity of DNA-binding proteins in vitro. This technique can be used to study protein-DNA interactions both outside and within cells.

ChIP-sequencing, also known as ChIP-seq, is a method used to analyze protein interactions with DNA. ChIP-seq combines chromatin immunoprecipitation (ChIP) with massively parallel DNA sequencing to identify the binding sites of DNA-associated proteins. It can be used to map global binding sites precisely for any protein of interest. Previously, ChIP-on-chip was the most common technique utilized to study these protein–DNA relations.

Epigenomics is the study of the complete set of epigenetic modifications on the genetic material of a cell, known as the epigenome. The field is analogous to genomics and proteomics, which are the study of the genome and proteome of a cell. Epigenetic modifications are reversible modifications on a cell's DNA or histones that affect gene expression without altering the DNA sequence. Epigenomic maintenance is a continuous process and plays an important role in stability of eukaryotic genomes by taking part in crucial biological mechanisms like DNA repair. Plant flavones are said to be inhibiting epigenomic marks that cause cancers. Two of the most characterized epigenetic modifications are DNA methylation and histone modification. Epigenetic modifications play an important role in gene expression and regulation, and are involved in numerous cellular processes such as in differentiation/development and tumorigenesis. The study of epigenetics on a global level has been made possible only recently through the adaptation of genomic high-throughput assays.

Chromatin Interaction Analysis by Paired-End Tag Sequencing is a technique that incorporates chromatin immunoprecipitation (ChIP)-based enrichment, chromatin proximity ligation, Paired-End Tags, and High-throughput sequencing to determine de novo long-range chromatin interactions genome-wide.

<span class="mw-page-title-main">Chromatin immunoprecipitation</span> Genomic technique

Chromatin immunoprecipitation (ChIP) is a type of immunoprecipitation experimental technique used to investigate the interaction between proteins and DNA in the cell. It aims to determine whether specific proteins are associated with specific genomic regions, such as transcription factors on promoters or other DNA binding sites, and possibly define cistromes. ChIP also aims to determine the specific location in the genome that various histone modifications are associated with, indicating the target of the histone modifiers. ChIP is crucial for the advancements in the field of epigenomics and learning more about epigenetic phenomena.

ChiRP-Seq is a high-throughput sequencing method to discover regions of the genome which are bound by a specific RNA. Recent studies have shown that a significant proportion of some genomes synthesize RNA that apparently do not code for proteins. The function of most of these non-coding RNA still has to be ascertained. Various genomic methods are being developed to map the functional association of these novel RNA to distinct regions of the genome to gain a better understanding of their function. ChiRP-Seq is one of these new methods which uses the massively parallel sequencing capability of 2nd generation sequencers to catalog the binding sites of these novel RNA molecules on a genome.

<span class="mw-page-title-main">ChIP-exo</span>

ChIP-exo is a chromatin immunoprecipitation based method for mapping the locations at which a protein of interest binds to the genome. It is a modification of the ChIP-seq protocol, improving the resolution of binding sites from hundreds of base pairs to almost one base pair. It employs the use of exonucleases to degrade strands of the protein-bound DNA in the 5'-3' direction to within a small number of nucleotides of the protein binding site. The nucleotides of the exonuclease-treated ends are determined using some combination of DNA sequencing, microarrays, and PCR. These sequences are then mapped to the genome to identify the locations on the genome at which the protein binds.

Selective microfluidics-based ligand enrichment followed by sequencing (SMiLE-seq) is a technique developed for the rapid identification of DNA binding specificities and affinities of full length monomeric and dimeric transcription factors in a fast and semi-high-throughput fashion.

<span class="mw-page-title-main">Single cell epigenomics</span> Study of epigenomics in individual cells by single cell sequencing

Single cell epigenomics is the study of epigenomics in individual cells by single cell sequencing. Since 2013, methods have been created including whole-genome single-cell bisulfite sequencing to measure DNA methylation, whole-genome ChIP-sequencing to measure histone modifications, whole-genome ATAC-seq to measure chromatin accessibility and chromosome conformation capture.

CUT&RUN sequencing, also known as cleavage under targets and release using nuclease, is a method used to analyze protein interactions with DNA. CUT&RUN sequencing combines antibody-targeted controlled cleavage by micrococcal nuclease with massively parallel DNA sequencing to identify the binding sites of DNA-associated proteins. It can be used to map global DNA binding sites precisely for any protein of interest. Currently, ChIP-Seq is the most common technique utilized to study protein–DNA relations, however, it suffers from a number of practical and economical limitations that CUT&RUN sequencing does not.

H3K9me3 is an epigenetic modification to the DNA packaging protein Histone H3. It is a mark that indicates the tri-methylation at the 9th lysine residue of the histone H3 protein and is often associated with heterochromatin.

BLESS, also known as breaks labeling, enrichment on streptavidin and next-generation sequencing, is a method used to detect genome-wide double-strand DNA damage. In contrast to chromatin immunoprecipitation (ChIP)-based methods of identifying DNA double-strand breaks (DSBs) by labeling DNA repair proteins, BLESS utilizes biotinylated DNA linkers to directly label genomic DNA in situ which allows for high-specificity enrichment of samples on streptavidin beads and the subsequent sequencing-based DSB mapping to nucleotide resolution.

H3K79me2 is an epigenetic modification to the DNA packaging protein Histone H3. It is a mark that indicates the di-methylation at the 79th lysine residue of the histone H3 protein. H3K79me2 is detected in the transcribed regions of active genes.

H4K20me is an epigenetic modification to the DNA packaging protein Histone H4. It is a mark that indicates the mono-methylation at the 20th lysine residue of the histone H4 protein. This mark can be di- and tri-methylated. It is critical for genome integrity including DNA damage repair, DNA replication and chromatin compaction.

H4K91ac is an epigenetic modification to the DNA packaging protein histone H4. It is a mark that indicates the acetylation at the 91st lysine residue of the histone H4 protein. No known diseases are attributed to this mark but it might be implicated in melanoma.

H3K23ac is an epigenetic modification to the DNA packaging protein Histone H3. It is a mark that indicates the acetylation at the 23rd lysine residue of the histone H3 protein.

CUT&Tag-sequencing, also known as cleavage under targets and tagmentation, is a method used to analyze protein interactions with DNA. CUT&Tag-sequencing combines antibody-targeted controlled cleavage by a protein A-Tn5 fusion with massively parallel DNA sequencing to identify the binding sites of DNA-associated proteins. It can be used to map global DNA binding sites precisely for any protein of interest. Currently, ChIP-Seq is the most common technique utilized to study protein–DNA relations, however, it suffers from a number of practical and economical limitations that CUT&RUN and CUT&Tag sequencing do not. CUT&Tag sequencing is an improvement over CUT&RUN because it does not require cells to be lysed or chromatin to be fractionated. CUT&RUN is not suitable for single-cell platforms so CUT&Tag is advantageous for these.

H3K36me2 is an epigenetic modification to the DNA packaging protein Histone H3. It is a mark that indicates the di-methylation at the 36th lysine residue of the histone H3 protein.

H3R17me2 is an epigenetic modification to the DNA packaging protein histone H3. It is a mark that indicates the di-methylation at the 17th arginine residue of the histone H3 protein. In epigenetics, arginine methylation of histones H3 and H4 is associated with a more accessible chromatin structure and thus higher levels of transcription. The existence of arginine demethylases that could reverse arginine methylation is controversial.

H3R2me2 is an epigenetic modification to the DNA packaging protein histone H3. It is a mark that indicates the di-methylation at the 2nd arginine residue of the histone H3 protein. In epigenetics, arginine methylation of histones H3 and H4 is associated with a more accessible chromatin structure and thus higher levels of transcription. The existence of arginine demethylases that could reverse arginine methylation is controversial.

References

  1. 1 2 3 4 5 6 7 8 9 Anders, Lars; Guenther, Matthew G; Qi, Jun; Fan, Zi Peng; Marineau, Jason J; Rahl, Peter B; Lovén, Jakob; Sigova, Alla A; Smith, William B; Lee, Tong Ihn; Bradner, James E; Young, Richard A (15 December 2013). "Genome-wide localization of small molecules". Nature Biotechnology. 32 (1): 92–96. doi:10.1038/nbt.2776. PMC   4189815 . PMID   24336317.
  2. ↑ Johnson, DS; Mortazavi, A; Myers, RM; Wold, B (Jun 8, 2007). "Genome-wide mapping of in vivo protein-DNA interactions" (PDF). Science. 316 (5830): 1497–502. Bibcode:2007Sci...316.1497J. doi:10.1126/science.1141319. PMID   17540862. S2CID   519841.
  3. 1 2 Squires, MS; Cooke, L; Lock, V; Qi, W; Lewis, EJ; Thompson, NT; Lyons, JF; Mahadevan, D (Apr 2010). "AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples". Molecular Cancer Therapeutics. 9 (4): 920–8. doi: 10.1158/1535-7163.MCT-09-1071 . PMID   20354122.
  4. ↑ Tung, SY; Hong, JY; Walz, T; Moazed, D; Liou, GG (Feb 2012). "Chromatin affinity-precipitation using a small metabolic molecule: its application to analysis of O-acetyl-ADP-ribose". Cellular and Molecular Life Sciences. 69 (4): 641–50. doi:10.1007/s00018-011-0771-x. PMC   3266462 . PMID   21796450.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.